BTIG analyst Jeet Mukherjee lowered the firm’s price target on Arvinas (ARVN) to $16 from $69 and keeps a Buy rating on the shares. The firm cites the company’s Q1 results and the re-prioritization of vepdegestrant’s development plans by discontinuing the first-line and second-line combo Phase 3 trials based on the outcome of VERITAC-2 and the view of a more niche utilization of SERDs to ESR1m patients, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN:
- Arvinas price target lowered to $19 from $26 at Wells Fargo
- Arvinas price target lowered to $14 from $24 at Piper Sandler
- Arvinas Holding Company: Buy Rating Affirmed Amidst Promising Vepdeg Potential and Strong Financial Position
- Arvinas downgraded to Hold from Buy at TD Cowen
- Arvinas price target lowered to $16 from $32 at Barclays